2024 KY AETC Conference: Caring for Vulnerable Populations

Utilizing Psychedelics to Provide Mental Health Support to Underserved and Vulnerable Populations

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: Jun 1, 2024
  • Expires: Jun 1, 2027
  • Average User Rating:
    ( Ratings)

This CE activity was recorded from the live event "KY AETC Annual Conference: Caring for Vulnerable Populations" dated April 26-27, 2024. If you claimed credit for the live event you should not claim credit for this module.


Deidre Lafferty Deidre Lafferty, MSSW, LCSW
Primary Therapist | Owner
Reclaim Life Mental Health Center
Albany, Oregon

Needs Statement

According to the CDC 36,136 people received an HIV diagnosis in the United States and dependent areas in 2021. The annual number of new diagnoses decreased 7% from 2017 to 2021. It is critical for professionals to have current knowledge to provide effective treatment and education for patients. The CDC also states that Kentucky is at high risk for an HIV outbreak if introduced into the drug using population. HIV therapy was previously limited due to lack of treatment options, but more therapy options increase choice for patient treatment and challenges for providers. Screening for drug misuse is critical to the prevention of or early intervention in addiction. 

Studies show that psilocybin is a safe and effective tool that can provide valuable benefit to a person's mental health and wellbeing. There is growing evidence showing that psilocybin can help provide relief from addiction, anxiety, depression, and other psychological issues like processing traumatic events.

Target Audience

Physicians, physician assistants, advanced practice nurses, nurses, pharmacists, dentists, social workers, health educators and therapists who currently provide or could provide care services to persons living with HIV/AIDS or Hepatitis C.


Upon completion of this activity, participants will be able to:
1. List the three components of psychedelic therapy in the Oregon Psilocybin Services model.
2. List at least three reasons a patient would not be a good fit for psilocybin services.
3. Assist patients in accessing psilocybin services.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Diedre Lafferty, MSSW, faculty for this event, is and owner of Reclaim Life, LLC, Life Trek, LLC, and Inner Guidance Services Inc. She is also executive director for Cap and Stem Northwest.
All of the relevant financial relationships listed for these individuals have been mitigated.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


This program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U1OHA30535 as part of an award totaling $4.2m. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.

“Funding for this presentation was made possible by cooperative agreement U1OHA30535 from the Health Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.”

This content is owned by the AETC, and is protected by copyright laws.  Reproduction or distribution of the content without written permission of the sponsor is prohibited, and may result in legal action.